View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 30, 2021

Leo Pharma partners with Veeva Systems to digitalise clinical trials

LEO Pharma will use Veeva’s CDMS, eConsent, eTMF, CTMS, Site Connect, ePRO, Virtual Visits, and eSource products.

Dermatology company Leo Pharma has entered a strategic technology partnership with software company Veeva Systems for patient-centric digital trials.

A provider of Cloud software for the life sciences industry, Veeva Systems will help Leo Pharma to digitalise its clinical trials.

The latest move builds on the successful integration of the Veeva Clinical Operations Suite.

Through this collaboration, LEO Pharma will use Veeva clinical products that include CDMS, eConsent, eTMF, CTMS, Site Connect, ePRO, Virtual Visits, and eSource.

Using these products, the company will complete its standardisation on existing Veeva clinical technology and be an early adopter of Veeva solutions.

Veeva CEO and founder Peter Gassner said: “We intend to help move the industry forward with a scalable digital trials platform that significantly improves the clinical trial process for patients, sites, and sponsors.”

LEO Pharma intends to obtain higher accuracy in clinical data, significantly improve patient experience and increase patient diversity by adopting the technology and optimised business processes.

It also plans to reduce clinical trial costs and time by 25%.

LEO Pharma Research and Development executive vice-president and head Jörg Möller said: “We’ve been exploring ways to transform clinical trials, but Covid-19 sped up this process. By promptly responding to changing market dynamics, we kept our trials going without delay.

“Partnering with Veeva supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business.”

In April 2021, Parexel and Veeva Systems announced plans to accelerate clinical trials through technology and process innovation, as part of a strategic collaboration.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU